Novartis has formed a new partnership to support the development of its drug candidate KDU731 to treat cryptosporidiosis, a parasitic disease characterised by diarrhoea.

KDU731 is being developed as an inhibitor of the cryptosporidium lipid kinase PI(4)K (phosphatidylinositol-4-OH kinase).

Go deeper with GlobalData

Go deeper with GlobalData

The gold standard of business intelligence.

Find out more

Discover B2B Marketing That Performs

Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.

Find out more

The drug candidate demonstrated favourable efficacy for treating cryptosporidium infection in preclinical studies and is currently being evaluated in safety studies before advancing into clinical trials.

Diarrhoeal diseases are reported to be the cause of around 525,000 childhood deaths each year, and cryptosporidiosis is said to be the second major factor behind infectious diarrhoea in children aged less than two years.

These statistics call for an urgent medical need requiring new and effective medications for cryptosporidiosis.

“We are committed to the fight against cryptosporidiosis and other infectious and neglected tropical diseases and are proud to work closely with the Bill & Melinda Gates Foundation and other partners in this effort.”

Under the latest collaboration, the firm will receive a $6.5m grant from the Bill & Melinda Gates Foundation intended to advance KDU731 development for treatment by the Novartis Institute for Tropical Diseases (NITD).

GlobalData Strategic Intelligence

US Tariffs are shifting - will you react or anticipate?

Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.

By GlobalData

NITD head Thierry Diagana said: “We are committed to the fight against cryptosporidiosis and other infectious and neglected tropical diseases and are proud to work closely with the Bill & Melinda Gates Foundation and other partners in this effort.

“Today’s global health issues cannot be solved by one organisation alone. Private companies, governments, non-governmental organisations, academia, and other stakeholders need to work together to create sustainable solutions.”

NITD primarily focuses on the discovery and development of new drugs for malaria, cryptosporidiosis, human African trypanosomiasis (sleeping sickness), chagas disease and leishmaniasis.

Pharmaceutical Technology Excellence Awards - Nominations Closed

Nominations are now closed for the Pharmaceutical Technology Excellence Awards. A big thanks to all the organisations that entered – your response has been outstanding, showcasing exceptional innovation, leadership, and impact.

Excellence in Action
Awarded the 2025 Pharmaceutical Technology Excellence Award for Business Expansion in Integrated Manufacturing, Upperton Pharma Solutions is rapidly expanding its UK GMP and sterile manufacturing footprint. Find out how Upperton’s integrated CDMO model helps pharma companies move from early development to clinical and niche commercial supply with fewer handovers and faster timelines.

Discover the Impact